In patients who are unable to receive platinum-based chemotherapy, cetuximab, an epidermal growth factor receptor chimeric IgG1 monoclonal antibody, was shown to improve survival in patients with locoregional advanced HNSCC as compared to radiation alone leading to its approval for use concurrently with radiation [62]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.